在接受意大利现有的生长激素临床制剂治疗的受试者中，抗生长激素抗体的高发生率。

High incidence of anti-GH antibodies in subjects treated with the GH clinical preparation available in Italy.

作者信息

Purrello F, Vigneri R, Belfiore A, Pezzino V, Squatrito S, Polosa P

机构信息

Istituto di Patologia Medica I, Università di Catania, Ospedale Garibaldi, Italy.

出版信息

J Endocrinol Invest. 1980 Jul-Sep;3(3):313-5. doi: 10.1007/BF03348283.

DOI:10.1007/BF03348283

PMID:7430559

Abstract

We have characterized the GH clinical preparation available in Italy (Grorm, Serono) by gel chromatography and immunoreactivity. Only 50-60% of this preparation can be identified with the active GH monomeric form. Both higher and lower molecular weight compounds are present as well. Then, using a radioimmunoassay technique, we looked for anti-GH antibodies in 21 subjects under Grorm treatment and found them in 6 paitents (28.6%). Two subjects having anti-GH antibodies with high affinity had a lower growth rate. These data suggest that anti-GH antibodies measurement is clinically useful in patients treated with this GH preparation. A more purified preparation should be used when a slowing down of the growth rate is observed in the presence of anti-GH antibodies.

摘要

我们通过凝胶色谱法和免疫反应性对意大利现有的生长激素临床制剂（Grorm，赛诺诺）进行了特性分析。该制剂中只有50%-60%可被鉴定为活性生长激素单体形式。同时还存在分子量更高和更低的化合物。然后，我们采用放射免疫测定技术，在21例接受Grorm治疗的受试者中检测抗生长激素抗体，结果在6例患者（28.6%）中发现了此类抗体。两名具有高亲和力抗生长激素抗体的受试者生长速率较低。这些数据表明，对于接受这种生长激素制剂治疗的患者，检测抗生长激素抗体具有临床意义。当在存在抗生长激素抗体的情况下观察到生长速率减慢时，应使用更纯化的制剂。